Fintel reports that on March 7, 2025, Stifel downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy to ...

J&J said it plans to “explore future development opportunities for aticaprant in other areas of high unmet need”. A statement ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...

NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been fil ...

Research analysts at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a research report issued to clients and investors on Tuesday, March ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report)‘s stock had its “sector perform” rating reaffirmed by investment ...

Neumora Therapeutics (NASDAQ:NMRA) stock drops 11% as Stifel downgrades nothing that J&J (JNJ) discontinues a drug similar to NMRA's lead asset. Read more here.

After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, ...

KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...